Related Experiment Videos
Antioxidant treatment of therapy-resistant idiopathic membranous nephropathy with probucol: a pilot study
Martin Haas1, Gert Mayer, Gerhard Wirnsberger
1Division of Nephrology and Dialysis, University of Vienna, Austria. Martin.Haas@akh-wien.ac.at
Background:
Proteinuria in Heymann's nephritis, an experimental rat model disease corresponding to membranous nephropathy, has been shown to be due to lipid peroxidation. Since the pathophysiology might be similar to idiopathic membranous nephropathy in humans, we performed a prospective multicenter trial to investigate the efficacy of the lipid peroxidation scavenger, probucol.
Methods:
Fifteen patients with biopsy-proven idiopathic membranous nephropathy resistant to conventional immunosuppressive therapy (n = 7) and/or ACEI treatment (n = 12) were recruited. Probucol (1 g/d orally) was administered for three months, followed by a washout period of four weeks, whereon lovastatin (10-20 mg/d orally) was administered for additional three months.
Results:
A significant reduction in proteinuria was seen during the probucol treatment (median (range): 6.4 (3.8-9.1) g/d vs. 4.7 (1.3-16) g/d; P < 0.05), with partial remission achieved in four patients. Three of these patients had previously been resistant to immunosuppressive therapy. Median protein excretion increased to pretreatment values during the washout period (6.2 (1.9-15) g/d; P < 0.05) and was not significantly different after the intake of lovastatin (4.9 (1.8-19) g/d; P = NS). None of the patients achieved partial remission during lovastatin therapy (P < 0.05 vs. probucol).
Conclusion:
The present study led us to conclude that proteinuria can be reduced by probucol in some patients with idiopathic membranous nephropathy. A randomized multicenter study to further elucidate the influence of lipid peroxidation scavengers on membranous nephropathy is warranted.
Insights
Probucol, a lipid peroxidation scavenger, significantly reduced proteinuria in patients with idiopathic membranous nephropathy. Further research is needed to confirm its efficacy in treating this kidney disease.
Area of Science:
- Nephrology
- Internal Medicine
- Pharmacology
Background:
- Idiopathic membranous nephropathy (IMN) is a leading cause of nephrotic syndrome in adults.
- Lipid peroxidation is implicated in the pathogenesis of IMN, similar to Heymann's nephritis in rats.
- Conventional therapies for IMN often have limited efficacy, necessitating novel treatment strategies.
Purpose of the Study:
- To investigate the efficacy of probucol, a lipid peroxidation scavenger, in reducing proteinuria in patients with biopsy-proven IMN.
- To evaluate the effect of probucol in patients resistant to standard immunosuppressive therapy and/or ACE inhibitors.
- To compare the effects of probucol with lovastatin in managing proteinuria in IMN.
Main Methods:
- A prospective multicenter trial involving 15 patients with IMN.
- Patients received oral probucol (1 g/d) for three months.
- A subsequent four-week washout period was followed by three months of oral lovastatin (10-20 mg/d).
Main Results:
- Probucol treatment led to a significant reduction in proteinuria (P < 0.05), with partial remission in four patients.
- Three patients who achieved remission were previously resistant to immunosuppressive therapy.
- Proteinuria returned to baseline during the washout period and did not significantly change with lovastatin therapy (P = NS).
Conclusions:
- Probucol demonstrates potential in reducing proteinuria in select patients with idiopathic membranous nephropathy.
- The findings suggest that targeting lipid peroxidation may be a viable therapeutic approach for IMN.
- A randomized, multicenter study is warranted to further validate the role of lipid peroxidation scavengers in IMN management.